All In Biotech

Drug Trial Radar · NCT06911112

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Mar 31, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Conditions

  • Major Depressive Disorder

Interventions

  • OsavampatorDrug

    Osavampator tablets

  • PlaceboDrug

    Matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56Time frame: Baseline, Day 56

Locations

42 sites in 5 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Huntsville, Alabama · Recruiting

  • Neurocrine Clinical Site

    Bryant, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Cerritos, California · Recruiting

  • Neurocrine Clinical Site

    Glendale, California · Recruiting

  • Neurocrine Clinical Site

    Irvine, California · Withdrawn

  • Neurocrine Clinical Site

    Redlands, California · Recruiting

  • Neurocrine Clinical Site

    San Francisco, California · Recruiting

  • Neurocrine Clinical Site

    Hollywood, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami, Florida · Active not recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Recruiting

  • Neurocrine Clinical Site

    Atlanta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Louisville, Kentucky · Recruiting

  • Neurocrine Clinical Site

    Boston, Massachusetts · Withdrawn

  • Neurocrine Clinical Site

    Saint Charles, Missouri · Active not recruiting

  • Neurocrine Clinical Site

    New York, New York · Recruiting

  • Neurocrine Clinical Site

    The Bronx, New York · Active not recruiting

  • Neurocrine Clinical Site

    Mason, Ohio · Recruiting

  • Neurocrine Clinical Site

    DeSoto, Texas · Recruiting

  • Neurocrine Clinical Site

    Houston, Texas · Recruiting

  • Neurocrine Clinical Site

    Charlottesville, Virginia · Recruiting

  • Neurocrine Clinical Site

    Kardzhali, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Plovdiv, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Rousse, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Sofia, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Sofia, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Varna, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Kaunas, Lithuania · Recruiting

  • Neurocrine Clinical Site

    Kaunas, Lithuania · Recruiting

  • Neurocrine Clinical Site

    Kaunas, Lithuania · Recruiting

  • Neurocrine Clinical Site

    Klaipėda, Lithuania · Withdrawn

  • Neurocrine Clinical Site

    Vilnius, Lithuania · Recruiting

  • Neurocrine Clinical Site

    Bucharest, Romania · Withdrawn

  • Neurocrine Clinical Site

    Bucharest, Romania · Withdrawn

  • Neurocrine Clinical Site

    Craiova, Romania · Recruiting

  • Neurocrine Clinical Site

    Oradea, Romania · Withdrawn

  • Neurocrine Clinical Site

    Banská Bystrica, Slovakia · Recruiting

  • Neurocrine Clinical Site

    Bojnice, Slovakia · Recruiting

  • Neurocrine Clinical Site

    Bratislava, Slovakia · Recruiting

  • Neurocrine Clinical Site

    Košice, Slovakia · Recruiting

  • Neurocrine Clinical Site

    Rimavská Sobota, Slovakia · Recruiting

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.